The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
Status:
Recruiting
Trial end date:
2025-06-24
Target enrollment:
Participant gender:
Summary
This is an open label, multicenter, randomized study in Chinese patients with RAS and BRAF
wild-type mCRC. Participants were randomly assigned to cetuximab + FOLFOX (group A) and
cetuximab + modified XELOX[mXELOX] (group B). All patients in groups A and B will be treated
until progression of disease(PD), death, intolerable toxicity or withdrawal of informed
consent, whichever occurs first.